Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of online meetings, phone calls, and deadlines has returned. But you knew this would happen, yes? After all the world, such as it is, keeps spinning no matter what. So time to give it a nudge in a better direction with a cup or three of stimulation. Our choice today is bananas Foster. Please feel free to join us. Meanwhile, here is the latest menu of tidbits to help you get started on your journey, which we hope is meaningful and productive. Best of luck and, of course, do stay in touch. …
A two-part message is permeating the halls of medicine and the fabric of society, sliding into medical school lectures, pediatrician offices, happy hours, and social feeds: Obesity is a chronic biological disease — and it is treatable with a new class of medications, STAT explains. The condition has long been framed as a result of poor lifestyle decisions and a failure of willpower — eating too much and exercising too little. But a new generation of highly effective obesity medications, and the overt and subtle messaging from the pharmaceutical companies making them, are starting to change the narrative.
Takeda Pharmaceutical will sell its dengue vaccine at a steep discount in emerging markets, The Japan Times writes. The cost for Qdenga in Indonesia will be about one-third its European price and the company will also sell the shot at a discount in Brazil. The recommended retail price for a course of two shots is about $80 out of pocket for Indonesians — compared with $238 in Germany. Even so, that could still be out of reach for many Indonesians, especially people living in rural areas who are most at risk of the disease. Indonesia had gross national income per capita of $3,870 in 2021, according to the World Bank.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect